The study was conducted to provide insight into real-world Bruton tyrosine kinase (BTK) inhibitor treatment patterns in mantle cell lymphoma, as current data are limited. A real-world analysis of ...
David J. Andorsky, MD, board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers, discussed findings from a study on patterns of Bruton tyrosine kinase (BTK) inhibitor care ...
Nurix Therapeutics (NRIX) has been able to post initial positive results from both of its early-stage studies using its protein degraders known as NX-2127 and NX-5948 for the treatment of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback